Human papillomavirus vaccine multivalent (V505) - Merck

Drug Profile

Human papillomavirus vaccine multivalent (V505) - Merck

Alternative Names: Broad-spectrum human papillomavirus vaccine - Merck; V-505

Latest Information Update: 10 Feb 2014

Price : $50

At a glance

  • Originator Merck & Co
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 24 Jun 2011 Merck & Co completes a phase IIa trial in Cervical cancer and Human papillomavirus infections in Australia and New Zealand (NCT00520598)
  • 22 Mar 2010 Phase-II development is ongoing in Australia and New Zealand
  • 25 Oct 2007 Phase-II clinical trials in Human papillomavirus infections in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top